M Singer's research while affiliated with University College London and other places

What is this page?


This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (1)


Table 1 Summary of randomized controlled trials (RCTs) of normobaric (A) and hyperbaric (B) oxygen treatment in the indications described in the text
Figure 4: The oxygen cascade during normoxia and hyperoxia. Of note, there is a large drop in partial pressure of oxygen (PO2) from the lung to the tissue, and a small difference in PO2 in the tissues in normoxaemia and hyperoxaemia. The increase in venous PO2 (shunting in the microvascular bed) is shown.
Figure 6: The mechanisms by which the superoxide ion (O2–) reduces the bioavailability of nitric oxide (NO) and thereby induces vasoconstriction by: reducing the L-arginine levels needed for NO production (1); reducing NO oxidase (NOS) function that catalyses conversion of L-arginine to NO (2); and reducing the unloading of NO from the haemoglobin molecule (3).
Figure 7: Overview of therapeutic mechanisms of hyperbaric oxygen (HBO) related to elevations of tissue oxygen tensions. The initial effects that occur due to increased production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) and their consequences are outlined. GF, growth factor; VEGF, vascular endothelial growth factor; HIF, hypoxia-inducible factor; SPCs, stem/progenitor cells; HO-1, haeme oxygenase-1; HSPs, heat shock proteins; SDF-1, stromal cell-derived factor 1. Modified from Thom [9].
The medical use of oxygen: A time for critical reappraisal
  • Literature Review
  • Full-text available

December 2013

·

1,276 Reads

·

191 Citations

Journal of Internal Medicine

·

M Singer

Oxygen treatment has been a cornerstone of acute medical care for numerous pathological states. Initially, this was supported by the assumed need to avoid hypoxaemia and tissue hypoxia. Most acute treatment algorithms, therefore, recommended the liberal use of a high fraction of inspired oxygen, often without first confirming the presence of a hypoxic insult. However, recent physiological research has underlined the vasoconstrictor effects of hyperoxia on normal vasculature and, consequently, the risk of significant blood flow reduction to the at-risk tissue. Positive effects may be claimed simply by relief of an assumed local tissue hypoxia, such as in acute cardiovascular disease, brain ischaemia due to, for example, stroke or shock or carbon monoxide intoxication. However, in most situations, a generalized hypoxia is not the problem and a risk of negative hyperoxaemia-induced local vasoconstriction effects may instead be the reality. In preclinical studies, many important positive anti-inflammatory effects of both normobaric and hyperbaric oxygen have been repeatedly shown, often as surrogate end-points such as increases in gluthatione levels, reduced lipid peroxidation and neutrophil activation thus modifying ischaemia-reperfusion injury and also causing anti-apoptotic effects. However, in parallel, toxic effects of oxygen are also well known, including induced mucosal inflammation, pneumonitis and retrolental fibroplasia. Examining the available 'strong' clinical evidence, such as usually claimed for randomized controlled trials, few positive studies stand up to scrutiny and a number of trials have shown no effect or even been terminated early due to worse outcomes in the oxygen treatment arm. Recently, this has led to less aggressive approaches, even to not providing any supplemental oxygen, in several acute care settings, such as resuscitation of asphyxiated newborns, during acute myocardial infarction or after stroke or cardiac arrest. The safety of more advanced attempts to deliver increased oxygen levels to hypoxic or ischaemic tissues, such as with hyperbaric oxygen therapy, is therefore also being questioned. Here, we provide an overview of the present knowledge of the physiological effects of oxygen in relation to its therapeutic potential for different medical conditions, as well as considering the potential for harm. We conclude that the medical use of oxygen needs to be further examined in search of solid evidence of benefit in many of the current clinical settings in which it is routinely used.

Download
Share

Citations (1)


... To ensure that there is sufficient oxygen to maintain cell viability without impeding vascularization, differentiation, tissue damage from inflammation, or the release of an excess of oxygen, it is vital to comprehend the oxygen requirements of specific tissues and the rate of vascularization into those tissues. Furthermore, hyperoxia can produce major hemodynamic changes (Cornet et al., 2013;Sjöberg and Singer, 2013) and has been shown to cause vasoconstriction in some vascular systems (coronary, cerebral, skeletal muscle, and retinal) (Messina et al., 1994;Kiss et al., 2002;Floyd et al., 2003;McNulty et al., 2007), but not all (renal, mesenteric) (Lang and Johnson, 1988;Sha et al., 1998), vascular beds. This vasoconstriction appears to occur primarily at the microvascular level, as large conduit arteries diameters remain constant (McNulty et al., 2007;Farquhar et al., 2009). ...

Reference:

Oxygen generating biomaterials at the forefront of regenerative medicine: advances in bone regeneration
The medical use of oxygen: A time for critical reappraisal

Journal of Internal Medicine